The Pharmacy Times® Insights video library presents one-on-one interviews with pharmacy experts, who examine the latest patient counseling tools and innovative solutions for the everyday practice and business.
What can we help you find?
A discussion on the use of BTK (Bruton’s tyrosine kinase) inhibitor monotherapy for newly diagnosed chronic lymphocytic leukemia (CLL) patients, with special consideration of the RESONATE trial regimen.
Experts in the field of chronic lymphocytic management (CLL) consider how MRD (minimum residual disease) testing affects the use of limited duration therapy.
Key opinion leaders consider the decision criteria for selecting a front-line therapy for patients with chronic lymphocytic leukemia (CLL).
Pharmacy experts discuss advancements and updates in therapies for chronic lymphocytic leukemia (CLL).
Paul Dobesh, PharmD, and James Groce III, PharmD, provide some final thoughts on the future of CAD/PAD management.
Key opinion leaders discuss the need to educate patients and physicians and the potential consequences of managing CAD/PAD without proper data support or understanding.
Experts in the field of CAD/PAD management provide personal insight into interchanging anticoagulants and minimizing confusion of the different DOACs at 2.5-mg strength.
Top pharmacists consider the reasons for delays in implementing new data into the treatment guidelines for CAD/PAD.
BC Childress, PharmD, MBA, MOL, BCACP, FASCP, Director of Pharmacy, Owensboro Health System in Owensboro, Kentucky, discusses the benefit of ready to use formulations of levothyroxine.
Key opinion leaders discuss the varying definitions of major bleeding as an adverse event in antithrombotic treatments.
BC Childress, PharmD, MBA, MOL, BCACP, FASCP, Director of Pharmacy, Owensboro Health System in Owensboro, Kentucky, discusses pharmacists' adherence to safety guidelines.
Paul Dobesh, PharmD, and James Groce, PharmD, provide an overview of the phase 3 double-blind COMPASS trial, with consideration of the regimen’s safety and efficacy end points.